FDA approves iberdomide (Zenbexus) for use with two other drugs in relapsed multiple myeloma.
The FDA approved iberdomide (Zenbexus) in combination with daratumumab and dexamethasone for multiple myeloma patients who have received at least one prior line of therapy. Detailed efficacy and safety data were not available. The approval applies to a specific relapsed/refractory patient population in the United States.
Why it matters
For patients with relapsed multiple myeloma, a new treatment option with a novel drug class is now available, providing an additional choice after prior therapy.
CHECKED · 1 SOURCE · UNCORROBORATED
← All news